RxDoctor Payments Data

Sumon Roy

Interventional Cardiology · Brockton, MANPI 1447601109

Payments from drug & device makers

What this record shows

This record is dominated by grants: $29,000 of the $44,828 with a category attached, or 64.7%. Medtronic accounts for 81.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $24,118 and has fallen 69.5% since, to $7,346 in 2025.

$44,828in general payments, 2019–2025

Across 282 payments — averaging $158.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$37K
  • Abiomed$2K
  • Abbott$2K
  • Edwards Lifesciences$1K
  • Novo Nordisk$413
  • Novartis$385
  • plus $2K from 16 others

What the payments were for

  • Grants$29,00065%
  • Travel & lodging$5,89513%
  • Food & beverage$9,93322%
  • Education$10%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,828 in reported general payments places this provider in the 75th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate13$145

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →